Detalhe da pesquisa
1.
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
Blood
; 139(9): 1340-1358, 2022 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788382
2.
ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model.
Blood
; 134(5): 432-444, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31151986
3.
Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
Blood
; 131(26): 2943-2954, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695515
4.
Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Cytotherapy
; 22(7): 369-376, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32303428
5.
Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
Blood
; 127(23): 2879-89, 2016 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27013443
6.
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
Haematologica
; 103(8): 1288-1297, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29773600
7.
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Blood
; 120(23): 4621-34, 2012 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-23034282
8.
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Blood
; 118(26): 6893-903, 2011 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-22042694
9.
OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway.
Br J Haematol
; 153(5): 623-33, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21470196
10.
The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia.
Blood Adv
; 5(16): 3152-3162, 2021 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424320
11.
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
Mol Cancer Ther
; 19(4): 1018-1030, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32024684
12.
Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Blood Adv
; 3(8): 1255-1266, 2019 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30987970
13.
Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.
Oncotarget
; 9(11): 9706-9713, 2018 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29515764
14.
MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.
Sci Signal
; 10(505)2017 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-29138297
15.
Oxidative stress-induced JNK/AP-1 signaling is a major pathway involved in selective apoptosis of myelodysplastic syndrome cells by Withaferin-A.
Oncotarget
; 8(44): 77436-77452, 2017 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29100399
16.
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
Exp Hematol
; 43(9): 770-4.e2, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25937048
17.
Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol.
Clin Cancer Res
; 18(17): 4600-11, 2012 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22791882
18.
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.
Cancer Cell
; 21(5): 694-708, 2012 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22624718
19.
FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
Clin Cancer Res
; 16(12): 3182-92, 2010 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20460491